Top

Published in:

01-02-2014 | Case Report

Tocilizumab Monotherapy in a Patient with Rheumatoid Arthritis and Iatrogenic Kaposi Sarcoma

Authors: Francesca Ingegnoli, Athanasia Tourlaki, Roberta Gualtierotti

Published in: Clinical Drug Investigation | Issue 2/2014

Abstract

Kaposi sarcoma (KS) is a human herpesvirus-8-associated lymphoangioproliferative neoplasm. Both human and viral interleukin-6 (IL-6) proteins seem to drive much of the clinical manifestations of KS, which provides a new target for intervention by using IL-6-neutralizing antibodies. We describe the clinical course of a patient in whom tocilizumab, a monoclonal anti-IL-6 receptor antibody approved for rheumatoid arthritis (RA) treatment, was effective not only in inducing RA remission but was also safe for KS.

Genovese MC, McKay JD, Nasonov EL, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum. 2008;58(10):2968–80.PubMedCrossRef

Dougados M, Kissel K, Sheeran T, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis. 2013;72(1):43–50.PubMedCentralPubMedCrossRef

Alten R, Maleitzke T. Tocilizumab: a novel humanized anti-interleukin 6 (IL-6) receptor antibody for the treatment of patients with non-RA systemic, inflammatory rheumatic diseases. Ann Med. 2013;45(4):357–63.PubMedCrossRef

Antman K, Chang Y. Kaposi’s sarcoma. N Engl J Med. 2000;342(14):1027–38.PubMedCrossRef

Mezalek ZT, Harmouche H, Attar NE, et al. Kaposi’s sarcoma in association with Behcet’s disease: case report and literature review. Semin Arthritis Rheum. 2007;36(5):328–31.PubMedCrossRef

Martínez-Martínez ML, Pérez-García LJ, Escario-Travesedo E, et al. Kaposi sarcoma associated with infliximab treatment. Actas Dermosifiliogr. 2010;101(5):462–4.PubMedCrossRef

Ursini F, Naty S, Mazzei V, et al. Kaposi’s sarcoma in a psoriatic arthritis patient treated with infliximab. Int Immunopharmacol. 2010;10(7):827–8.PubMedCrossRef

Cohen CD, Horster S, Sander CA, et al. Kaposi’s sarcoma associated with tumour necrosis factor alpha neutralising therapy. Ann Rheum Dis. 2003;62(7):684.PubMedCrossRef

Law AB, Ryan G, Lade S, et al. Development of Kaposi’s sarcoma after complete remission of multicentric Castlemans disease with rituximab therapy in a HHV8-positive, HIV-negative patient. Int J Hematol. 2010;91(2):347–8.PubMedCrossRef

10.

Nicoli P, Familiari U, Bosa M, et al. HHV8-positive, HIV-negative multicentric Castleman’s disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma. Int J Hematol. 2009;90(3):392–6.PubMedCrossRef

11.

Terasaki Y, Okumura H, Saito K, et al. HHV-8/KSHV-negative and CD20-positive primary effusion lymphoma successfully treated by pleural drainage followed by chemotherapy containing rituximab. Intern Med. 2008;47(24):2175–8.PubMedCrossRef

12.

Pantanowitz L, Früh K, Marconi S, et al. Pathology of rituximab-induced Kaposi sarcoma flare. BMC Clin Pathol. 2008;23(8):7.CrossRef

13.

Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 2008;112(10):3959–64.PubMedCrossRef

14.

Suthaus J, Stuhlmann-Laeisz C, Tompkins VS, et al. HHV-8-encoded viral IL-6 collaborates with mouse IL-6 in the development of multicentric Castleman disease in mice. Blood. 2012;119(22):5173–81.PubMedCrossRef

15.

Morris VA, Punjabi AS, Wells RC, et al. The KSHV viral IL-6 homolog is sufficient to induce blood to lymphatic endothelial cell differentiation. Virology. 2012;428(2):112–20.PubMedCentralPubMedCrossRef

16.

An J, Lichtenstein AK, Brent G, et al. The Kaposi sarcoma-associated herpesvirus (KSHV) induces cellular interleukin 6 expression: role of the KSHV latency-associated nuclear antigen and the AP1 response element. Blood. 2002;99(2):649–54.PubMedCrossRef

17.

Beck JT, Hsu SM, Wijdenes J, et al. Alleviation of systemic manifestations of Castleman’s disease by monoclonal anti-interleukin-6 antibody. N Engl J Med. 1994;330(9):602–5.PubMedCrossRef

Title: Tocilizumab Monotherapy in a Patient with Rheumatoid Arthritis and Iatrogenic Kaposi Sarcoma
Authors: Francesca Ingegnoli
Athanasia Tourlaki
Roberta Gualtierotti
Publication date: 01-02-2014
Publisher: Springer International Publishing
Published in: Clinical Drug Investigation / Issue 2/2014
Print ISSN: 1173-2563
Electronic ISSN: 1179-1918
DOI: https://doi.org/10.1007/s40261-013-0159-9

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Tocilizumab Monotherapy in a Patient with Rheumatoid Arthritis and Iatrogenic Kaposi Sarcoma

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2014

Insulin Degludec: Pharmacokinetic Properties in Subjects with Hepatic Impairment

Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA

Efficacy, Safety, and Tolerability of Pantoprazole Magnesium in the Treatment of Reflux Symptoms in Patients with Gastroesophageal Reflux Disease (GERD): A Prospective, Multicenter, Post-Marketing Observational Study

Cost Effectiveness of Adding Dapagliflozin to Insulin for the Treatment of Type 2 Diabetes Mellitus in the Netherlands

Pharmacokinetics, Safety and Tolerability of Rotigotine Transdermal Patch in Healthy Japanese and Caucasian Subjects

Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA